Tag: Securities Act Sections 17(a)(2) and 17(a)(3)

SEC charges Zymergen for “unsupported hype” in its IPO

The SEC has announced settled charges against Zymergen, which, prior to its recent bankruptcy and ultimate liquidation, was a biotech “focused on the manufacture of novel materials, including optical films used in electronic screens.” The SEC charged that, in its $530 million IPO in 2021, Zymergen misled “IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline.”  According to  the Director of the SEC’s San Francisco Regional Office,  “[p]re-revenue and early-stage companies that seek to tap the capital markets must do so with reasonable estimates of their market potential….Today’s order finds that Zymergen failed to satisfy this obligation when it misled investors with what amounted to unsupported hype.” The company agreed to pay a civil penalty of $30 million. In the meantime, Bloomberg reports that a federal district court has recently allowed claims by Zymergen investors to proceed against several VC funds (along with the company, the board, the underwriters, etc).   The investors contended that, among other things, the levers provided in the company’s governing documents allowed the VC funds to “control[] the company in the lead-up to its initial public offering” and claimed that they were “responsible for misleading IPO papers before the biological manufacturing company imploded.”